SATURDAY, 15 JUNE 2019

Orthotic treatment: is it in or out?

**OP0337-HPR**

**EFFECTIVENESS OF CUSTOMIZED INSOLES IN PATIENTS WITH MORTON’S NEUROMA: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL**

Hilda Oliveira, Anamaria Jones, Fabio Jennings, Mariana Vassalli, Andre Roserfeld, Jamil Natour. Universidade Federal de São Paulo, São Paulo, Brazil

**Background:** Morton’s neuroma (MN) is a benign enlargement of the third common digital branch of the medial plantar nerve. The most common symptom is burning pain in the plantar foot located between the metatarsal heads, often radiating to the two corresponding toes. Treatment can be surgical or conservative, which consists of decreasing nerve pressure and irritation through therapies that promote analgesia, patient education, and plantar orthosis. The custom insole prescriptions are aimed at relieving the pressure in the MN region and to redistribute pressure throughout the sole of the foot. There is no study evaluating the effect of insoles in patients with MN.

**Objectives:** The aim of the present study was to assess the effectiveness of a customized insole with metatarsal and arch support on pain in patients with Morton’s neuroma and the impact of this insole on function, load distribution in the plantar region, gait, quality of life and satisfaction with insole use.

**Methods:** A randomized, controlled, double-blind, clinical trial was carried out with intent-to-treat analysis. Seventy-two patients with MN were randomly allocated into a study group (n=36) and control group (n=36). One week following the baseline evaluation, the study group received a customized insole with metatarsal and arch support made of ethyl vinyl acetate and the control group received a flat insole of the same material, color and density. The groups were evaluated after 6, 12 and 24 weeks of insole use. The following assessment parameters were employed: pain when walking, on palpation and at rest (END); paresthesia (ENP); quality of life (SF-36); foot function (FFI and FHSQ); six-minute walk test (6MWT) and foot pressure analysis using the AM Cube FootWalk Pro program.

**Results:** The groups were homogeneous regarding the majority of variables at baseline. In the comparisons over time, statistically significant differences between groups were found for pain when walking (p=0.048), in the general health domain (p=0.001) and physical activity located (p=0.025) in the FHSQ questionnaire, in the general FFI questionnaire score (p=0.012) and in the functional capacity domain of the SF-36 questionnaire (p=0.046). For pain at rest and palpation, in the domains of the FFI, some parameters of the FHSQ (vigor, pain, function and general health of the foot) and quality of life (limitation by physical aspects, bodily pain and vitality), we observed improvement in both groups with no statistically significant difference between them. No change was observed in the baropodometry parameters with the use of the insole.

**Conclusion:** A customized insole with metatarsal and arch support reduce pain when walking and improve function of patients with MN.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.2567

---

**SATURDAY, 15 JUNE 2019

Current treatment of vasculitis,**

**OP0338**

**LOW-DOSE IL-2 SELECTIVELY RESTORES REGULATORY T CELLS IN PATIENTS WITH BEHÇET’S DISEASE**

Xiaoying Liu, Gaiqin Chai. The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China

**Background:** The lack of CD4+CD25+Foxp3+ regulatory cell (Treg) has been associated with human systemic autoimmune diseases, such as rheumatoid arthritis (RA). IL-2 is an essential growth and survival factor for Treg cells. However, the significance of Treg cells in the pathogenesis and the effect of low dose of IL-2 on Behcet’s disease (BD) are rarely reported.

**Objectives:** To investigate the significance of Treg cells and the effect of low dose IL-2 on BD.

**Methods:** Eighty patients with BD and seventy healthy donors were enrolled. CD4+ T cell subsets in peripheral blood mononuclear cells from these people were measured by multicolour flow cytometry. Twenty-six patients were treated daily with subcutaneous injections of 0.5 million IU of human IL-2 for five consecutive days, CD4+ T cell subsets were analysed before and after treatment by flow cytometry.

**Results:** Compared to health control, the absolute counts of circulating Treg cells were significantly decreased in patients with BD (median:29.93 cells/ul VS median:33.16 cells/ul, P=0.039) and it is negative correlation with disease activity. While the ratios of Th17/Treg in patients with BD (median:0.29) were significantly higher than those of health control (median:0.2). No difference in the absolute counts of circulating Th17 cells (CD4+IL-17+) between patients with BD and health control. Treatment of patients with BD with a low-dose IL-2 selectively increased the absolute counts of Treg cells, from a median of 18.97 cells/ul to 74.68 cells/ul (at 5 days) (P<0.001). No significant difference was observed in the absolute counts of circulating Th17, Th1 and Th2 cells after IL-2 treatment.

**Conclusion:** Th17/Treg cells may play a role in the pathogenesis of patients with BD, low-dose IL-2 proposes a selective biological treatment strategy by restoring immune tolerance.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.2567

---

**SATURDAY, 15 JUNE 2019**

**TOCILIZUMAB IN GIANT CELL ARTERITIS. MONOTHERAPY VERSUS COMBINED WITH CONVENTIONAL IMMUNOSUPPRESSIVE DRUGS**


**Background:** Giant cell arteritis (GCA) can be refractory to corticosteroid therapy. Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no studies comparing the efficacy and safety when using TCZ as monotherapy or in combination with conventional immunosuppressive drugs in GCA.

**Objectives:** Our aim was to compare efficacy and safety of TCZ combined or in monotherapy in GCA.

**Methods:** Multicenter study on 134 patients with refractory GCA who received TCZ therapy as monotherapy or combined with conventional immunosuppressive drugs.

**Results:** We evaluated 134 patients (101 women) with a mean age of 73.0±8.8 years. TCZ was prescribed as monotherapy in 82 (62.2%) cases and combined with conventional immunosuppressive drugs in 52 (38.8%) patients: MTX (n=48), AZA (n=9), and LN (n=1). A comparative study between both groups is summarized in **Table 1.**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Monotherapy (n=82)</th>
<th>Combination (n=52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>73±8.8</td>
<td>73±8.8</td>
</tr>
<tr>
<td>Gender (women)</td>
<td>67</td>
<td>35</td>
</tr>
<tr>
<td>Disease activity (mean)</td>
<td>0.9</td>
<td>1.1</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>0.4</td>
<td>0.6</td>
</tr>
<tr>
<td>AIMS</td>
<td>36</td>
<td>33</td>
</tr>
<tr>
<td>ACR</td>
<td>0.9</td>
<td>1.1</td>
</tr>
<tr>
<td>Percentage of patients in remission</td>
<td>72%</td>
<td>72%</td>
</tr>
<tr>
<td>Time to remission (months)</td>
<td>2.1</td>
<td>2.3</td>
</tr>
</tbody>
</table>

**Conclusion:** Prolonged remission, absence of clinical symptoms and signs and normalization of the acute phase reactants for at least 6 months. Relapse, recurrence of signs or symptoms of GCA and/or ESR >20 mm/h in men or >25 mm/h in women, and/or serum CRP >0.5 mg/L related to GCA, both before and after starting TCZ therapy.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.2567